Clearmind Medicine Inc.

Clearmind Medicine Inc. announced its formal response to the U.S. Department of Health and Human Services (HHS) Request for Information (RFI) regarding addiction treatment innovations. The company proposed an innovative model for Alcohol Use Disorder (AUD) treatment, highlighting its proprietary MEAI-based candidate CMND-100 as a non-hallucinogenic neuroplastogen. This submission is part of the "Great American Recovery Initiative" and aims to position CMND-100 as a scalable, at-home solution for the millions affected by AUD.

Clearmind Medicine Inc. announced it has submitted a formal response to the U.S. Department of Health and Human Services (HHS) Request for Information (RFI). The submission highlights the potential of its MEAI-based candidate, CMND-100, as an innovative, non-hallucinogenic neuroplastogen for the treatment of Alcohol Use Disorder (AUD) and binge behaviors. Clearmind proposes an inexpensive, scalable, and clinically effective treatment model, emphasizing the drug's low abuse potential and ability to support moderation and long-term recovery for the approximately 10% of the U.S. population affected by AUD.

Clearmind Medicine Inc. announced the successful completion of a formulation feasibility study for intranasal delivery of its proprietary MEAI (5-Methoxy-2-aminoindane). This development supports a potential new additional route of administration for MEAI, initially targeting alcohol use disorder (AUD). The study confirmed MEAI's compatibility and suitability for intranasal administration, resulting in a stable and fully soluble solution, which the company believes will enhance therapeutic potential and patient experience.

Clearmind Medicine Inc. announced continued progress in evaluating intranasal delivery of its proprietary MEAI (5-Methoxy-2-aminoindane) as a potential additional route of administration for alcohol use disorder (AUD). Initial formulation feasibility studies successfully demonstrated that MEAI can be incorporated into the formulation, resulting in a stable and fully soluble solution. This development aims to enhance therapeutic potential and improve patient experience for AUD, which remains a significant unmet medical need.

Clearmind Medicine Inc. announced the successful completion of treatment for all participants in Part A of its ongoing FDA-regulated Phase I/II clinical trial. The trial is evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD), with all 24 participants across four cohorts having completed treatment. The company is now assessing the data and intends to initiate the next stage of the clinical program, reflecting a significant milestone in its drug development.

Clearmind Medicine Inc. announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial for CMND-100, a therapeutic candidate for Alcohol Use Disorder (AUD). All 24 participants across the four cohorts have completed treatment according to the study protocol. The company is now assessing the collected data and intends to advance to the next stage of the clinical program, involving AUD patients, assuming favorable results. This multicenter trial is being conducted under FDA oversight at leading research centers in the United States and Israel.

Clearmind Medicine Inc. announced it has been granted U.S. Patent No. 12,350,242, titled "BINGE BEHAVIOR REGULATORS," by the United States Patent and Trademark Office (USPTO). The patent covers innovative compositions and methods utilizing its MEAI molecule to regulate binge behaviors, including excessive drinking, eating, and gambling. This milestone expands Clearmind's global patent portfolio to 32 granted patents, reinforcing its leadership in psychedelic-based therapies and advancing clinical programs for binge-related disorders.

Clearmind Medicine Inc. announced the successful completion of dosing for all 24 participants in Part A of its ongoing FDA-regulated Phase I/II clinical trial. The trial is evaluating CMND-100, a proprietary drug candidate, for the treatment of Alcohol Use Disorder (AUD). Interim results from the first three cohorts have indicated a strong safety profile, which is encouraging as the program advances under FDA oversight.

Clearmind Medicine Inc. announced the successful completion of dosing for all 24 participants in Cohorts 1 through 4 of Part A of its ongoing Phase I/II clinical trial. The trial is evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD). Interim results from the first three cohorts continue to show a strong safety profile, and the trial is being conducted under FDA oversight at leading clinical sites.

Clearmind Medicine Inc. reported its unaudited condensed interim consolidated financial statements for the three and six months ended April 30, 2026. The company experienced a significant increase in net loss for both periods, with the six-month loss reaching $5,902,236 compared to $1,855,549 in the prior year. Despite the widening loss, total assets more than doubled to $14,523,512, and shareholders' equity saw a substantial rise to $11,490,741, largely due to financing activities including share issuances and convertible loan conversions. Operating expenses also increased significantly.